Serum MicroRNA 143 and MicroRNA 215 As Potential Biomarkers for the Diagnosis of Chronic Hepatitis and Hepatocellular Carcinoma

Overview

Journal Diagn Pathol

Publisher Biomed Central

Specialty Pathology

Date 2014 Jul 5

PMID 24993656

Citations 43

Authors

Zhu-Qing Zhang

Hua Meng

Nan Wang

Li-Na Liang

Li-Na Liu

Shu-ming Lu

Yong Luan

Affiliations

Soon will be listed here.

Abstract

Background: Hepatocellular carcinoma (HCC) is regarded as one of the most common malignancies and among the leading causes of cancer death among the whole world. The most urgent needs are to find sensitive markers for early diagnosis or monitor postoperative recurrence and to give adequate treatment for HCC. MicroRNAs (miRNAs) are reported as a group of small non-coding RNAs that can function as endogenous RNA interference to regulate expression of the targeted genes. This study was conducted to detect the application of miR-143 and miR-215 in the diagnosis of HCC.

Methods: A total of 340 serum samples (127 samples from controls, 118 samples from hepatitis and 95 samples from HCC patients) were collected. The levels of the two mature miRNAs (miR-143 and miR-215) were detected by probe-based stem-loop quantitative reverse-transcriptase PCR (RT-qPCR) in controls, hepatitis and HCC patients. Besides, the relationship between miR-143 and miR-215 levels and clinical and pathological factors was explored.

Results: We found that the expression of serum miR-215 was distinctly increased in chronic hepatitis compared with controls (mean ± SD: 6.79 ± 0.72 vs. 3.46 ± 0.37, P < 0.001 and mean ± SD: 8.38 ± 0.87 vs. 3.46 ± 0.37, P < 0.001). In addition, we conduct ROC analyses to detect the potential application of miR-143 and miR-215 in the diagnosis of chronic hepatitis and HCC. Our results showed that miR-143 and miR-215 might be a potential biomarker for the hepatitis and HCC.

Conclusions: In conclusion, the expression of miR-143 and miR-215 in serum were significantly up-regulated in patients with chronic hepatitis and HCC. Due to its reasonable sensitivity and specificity for both diseases, miR-143 and miR-215 could be as potential circulating biomarkers.

Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1048932281272754.

Citing Articles

Recent advances in optical aptasensors for biomarkers in early diagnosis and prognosis monitoring of hepatocellular carcinoma.

Dong J, Wang R, Yuan N, Guo J, Yu X, Peng A Front Cell Dev Biol. 2023; 11:1160544.

PMID: 37143897 PMC: 10152369. DOI: 10.3389/fcell.2023.1160544.

Diagnostic implication of a circulating serum-based three-microRNA signature in hepatocellular carcinoma.

Yousuf T, Dar S, Bangri S, Choh N, Rasool Z, Shah A Front Genet. 2022; 13:929787.

PMID: 36457743 PMC: 9705795. DOI: 10.3389/fgene.2022.929787.

Oncogenic Dysregulation of Circulating Noncoding RNAs: Novel Challenges and Opportunities in Sarcoma Diagnosis and Treatment.

Chellini L, Palombo R, Riccioni V, Paronetto M Cancers (Basel). 2022; 14(19).

PMID: 36230599 PMC: 9562196. DOI: 10.3390/cancers14194677.

Post-Transcriptional Effects of miRNAs on PCSK7 Expression and Function: miR-125a-5p, miR-143-3p, and miR-409-3p as Negative Regulators.

Malakootian M, Naeli P, Mowla S, Seidah N Metabolites. 2022; 12(7).

PMID: 35888711 PMC: 9323720. DOI: 10.3390/metabo12070588.

Prognostic MicroRNA Panel for HCV-Associated HCC: Integrating Computational Biology and Clinical Validation.

Dabbish A, Abdelzaher H, Abohawya M, Shamma S, Mahmoud Y, Maged A Cancers (Basel). 2022; 14(13).

PMID: 35804809 PMC: 9265118. DOI: 10.3390/cancers14133036.

References

Xiao F, Zhang W, Zhou L, Xie H, Xing C, Ding S . microRNA-200a is an independent prognostic factor of hepatocellular carcinoma and induces cell cycle arrest by targeting CDK6. Oncol Rep. 2013; 30(5):2203-10. DOI: 10.3892/or.2013.2715. View

Chen Q, Ge X, Zhang Y, Xia H, Yuan D, Tang Q . Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer. Oncol Rep. 2014; 31(4):1863-70. DOI: 10.3892/or.2014.3004. View

Luo J, Chen M, Huang H, Yuan T, Zhang M, Zhang K . Circulating microRNA-122a as a diagnostic marker for hepatocellular carcinoma. Onco Targets Ther. 2013; 6:577-83. PMC: 3666878. DOI: 10.2147/OTT.S44215. View

Abdel-Wahab M, El-Ghawalby N, Mostafa M, Sultan A, El-Sadany M, Fathy O . Epidemiology of hepatocellular carcinoma in lower Egypt, Mansoura Gastroenterology Center. Hepatogastroenterology. 2007; 54(73):157-62. View

Gyugos M, Lendvai G, Kenessey I, Schlachter K, Halasz J, Nagy P . MicroRNA expression might predict prognosis of epithelial hepatoblastoma. Virchows Arch. 2014; 464(4):419-27. DOI: 10.1007/s00428-014-1549-y. View

Senanayake U, Das S, Vesely P, Alzoughbi W, Frohlich L, Chowdhury P . miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms. Carcinogenesis. 2012; 33(5):1014-21. DOI: 10.1093/carcin/bgs126. View

Yang Y, Gu X, Zhou M, Xiang J, Chen Z . Serum microRNAs: A new diagnostic method for colorectal cancer. Biomed Rep. 2014; 1(4):495-498. PMC: 3917018. DOI: 10.3892/br.2013.109. View

Fu Y, Wei X, Tang C, Li J, Liu R, Shen A . Circulating microRNA-101 as a potential biomarker for hepatitis B virus-related hepatocellular carcinoma. Oncol Lett. 2013; 6(6):1811-1815. PMC: 3834113. DOI: 10.3892/ol.2013.1638. View

Dogan E, Yalcin S, Koca D, Olmez A . Clinicopathological characteristics of hepatocellular carcinoma in Turkey. Asian Pac J Cancer Prev. 2012; 13(6):2985-90. DOI: 10.7314/apjcp.2012.13.6.2985. View

10.

Gui J, Tian Y, Wen X, Zhang W, Zhang P, Gao J . Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond). 2010; 120(5):183-93. PMC: 2990200. DOI: 10.1042/CS20100297. View

11.

Liu A, Yao T, Wang W, Wong K, Lee N, Fan S . Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open. 2012; 2(2):e000825. PMC: 3308260. DOI: 10.1136/bmjopen-2012-000825. View

12.

Kojiro M, Kawabata K, Kawano Y, Shirai F, Takemoto N, Nakashima T . Hepatocellular carcinoma presenting as intrabile duct tumor growth: a clinicopathologic study of 24 cases. Cancer. 1982; 49(10):2144-7. DOI: 10.1002/1097-0142(19820515)49:10<2144::aid-cncr2820491026>3.0.co;2-o. View

13.

Naito Y, Sakamoto N, Oue N, Yashiro M, Sentani K, Yanagihara K . MicroRNA-143 regulates collagen type III expression in stromal fibroblasts of scirrhous type gastric cancer. Cancer Sci. 2013; 105(2):228-35. PMC: 4317817. DOI: 10.1111/cas.12329. View

14.

Zhang X, Liu S, Hu T, Liu S, He Y, Sun S . Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology. 2009; 50(2):490-9. DOI: 10.1002/hep.23008. View

15.

Bao Y, Cao Q, Yang Y, Mao R, Xiao L, Zhang H . Expression and prognostic significance of golgiglycoprotein73 (GP73) with epithelial-mesenchymal transition (EMT) related molecules in hepatocellular carcinoma (HCC). Diagn Pathol. 2013; 8:197. PMC: 3924912. DOI: 10.1186/1746-1596-8-197. View

16.

Su Z, Zhao J, Rong Z, Geng W, Wu Y, Qin C . Upregulation of microRNA-25 associates with prognosis in hepatocellular carcinoma. Diagn Pathol. 2014; 9:47. PMC: 4016611. DOI: 10.1186/1746-1596-9-47. View

17.

Ronald J, Katzenberg R, Nielsen C, Jae H, Hofmann L, Gambhir S . MicroRNA-regulated non-viral vectors with improved tumor specificity in an orthotopic rat model of hepatocellular carcinoma. Gene Ther. 2013; 20(10):1006-13. PMC: 3864878. DOI: 10.1038/gt.2013.24. View

18.

Cui M, Xiao Z, Sun B, Wang Y, Zheng M, Ye L . Involvement of cholesterol in hepatitis B virus X protein-induced abnormal lipid metabolism of hepatoma cells via up-regulating miR-205-targeted ACSL4. Biochem Biophys Res Commun. 2014; 445(3):651-5. DOI: 10.1016/j.bbrc.2014.02.068. View

19.

Wang L, Yao M, Dong Z, Zhang Y, Yao D . Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring. Tumour Biol. 2013; 35(1):9-20. PMC: 3907675. DOI: 10.1007/s13277-013-1141-0. View

20.

Zhao J, Lu Q, Zhu J, Fu J, Chen Y . Prognostic value of miR-96 in patients with acute myeloid leukemia. Diagn Pathol. 2014; 9:76. PMC: 3975266. DOI: 10.1186/1746-1596-9-76. View